MARKET

PTCT

PTCT

Ptc Therapeutics
NASDAQ
75.96
-0.23
-0.30%
After Hours: 75.96 0 0.00% 17:56 12/31 EST
OPEN
75.96
PREV CLOSE
76.19
HIGH
76.98
LOW
75.59
VOLUME
961.81K
TURNOVER
--
52 WEEK HIGH
87.50
52 WEEK LOW
35.95
MARKET CAP
6.10B
P/E (TTM)
8.90
1D
5D
1M
3M
1Y
5Y
1D
What's Going On With Royalty Pharma Stock Wednesday?
Benzinga · 12/31/2025 15:47
Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge
Seeking Alpha · 12/30/2025 13:57
Royalty Pharma Acquires Remaining Evrysdi Royalties From PTC Therapeutics
NASDAQ · 12/30/2025 02:15
Royalty Pharma buys remaining royalty interest in Roche drug Evrysdi
Seeking Alpha · 12/29/2025 22:13
Royalty Pharma Acquires Remaining Evrysdi Royalty Interest for $240 Million
Reuters · 12/29/2025 21:40
PTC Therapeutics Fully Monetizes Evrysdi Royalty Interest
TipRanks · 12/29/2025 21:35
PTC THERAPEUTICS INC - CO, ROYALTY PHARMA INVESTMENTS 2019 ICAV, ROYALTY PHARMA PLC ENTER AMENDMENT NO. 2 TO PURCHASE AGREEMENT
Reuters · 12/29/2025 21:14
PTC THERAPEUTICS INC - SELLS RETAINED ROYALTY INTEREST TO RPI FOR $240 MLN - SEC FILING
Reuters · 12/29/2025 21:14
More
About PTCT
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).

Webull offers PTC Therapeutics, Inc. stock information, including NASDAQ: PTCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTCT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PTCT stock methods without spending real money on the virtual paper trading platform.